Lipopolysaccharide-induced inflammatory response

The entry "Lipopolysaccharide-induced inflammatory response" refers to a biological process, not a specific, canonical molecule, receptor, or protein. Lipopolysaccharide (LPS), a major component of the outer membrane of Gram-negative bacteria, acts as a strong pro-inflammatory stimulus by engaging pattern-recognition receptors, most notably Toll-like receptor 4 (TLR4), on immune and structural cells[2][3][1]. This interaction rapidly triggers downstream signaling cascades such as NF-κB activation, leading to expression and secretion of cytokines and chemokines including IL-6, TNF-α, IL-1β, IL-8, CCL2, and CCL5, and the subsequent inflammatory cascade[1][2][4][5]. These responses form key cellular and molecular mechanisms in host defense but, when excessive or dysregulated, underlie pathologies such as sepsis, acute lung injury, and neuroinflammation[3][2][5]. While drugs can modulate the LPS-induced inflammatory response via targeting TLR4 or its downstream pathways, the response itself is not a single molecular therapeutic target, but a process model used widely in experimental research into inflammation and immunity. **Note:** - This entry is scientifically incorrect as a "target molecule or receptor"; it instead describes a cellular or organismal process initiated by a molecular interaction (e.g., LPS-TLR4). - For structured information, the appropriate molecular target for most LPS-induced responses is "Toll-like receptor 4 (TLR4)".

Other names

LPS-induced inflammatory responseEndotoxin-induced inflammationLipopolysaccharide-induced inflammation

Inhibition of TLR4 signaling; NF-κB inhibition; Suppression of cytokine release; Scavenging reactive oxygen species; Inhibition of COX-2 and iNOS